Revenue grew to £20.0m in FY2025, driven by strong NIPT and instrumentation sales, while EBITDA loss narrowed to £7.8m. Cash reserves of £19.1m enabled the acquisition of Southern Cross Diagnostics, and the company remains focused on R&D and double-digit growth targets.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.